Avalo Therapeutics, Inc. (AVTX)
19.59
-0.46
(-2.29%)
USD |
NASDAQ |
Aug 28, 16:00
19.60
+0.01
(+0.05%)
After-Hours: 20:00
Avalo Therapeutics Cash from Operations (Quarterly) : -19.99M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -19.99M |
| March 31, 2026 | -17.69M |
| December 31, 2025 | -14.25M |
| September 30, 2025 | -16.36M |
| June 30, 2025 | -11.39M |
| March 31, 2025 | -9.457M |
| December 31, 2024 | -15.04M |
| September 30, 2024 | -11.53M |
| June 30, 2024 | -16.28M |
| March 31, 2024 | -6.202M |
| December 31, 2023 | -2.766M |
| September 30, 2023 | -6.836M |
| June 30, 2023 | -11.03M |
| March 31, 2023 | -10.05M |
| December 31, 2022 | -3.94M |
| September 30, 2022 | 5.726M |
| June 30, 2022 | -12.47M |
| March 31, 2022 | -16.07M |
| December 31, 2021 | -17.10M |
| September 30, 2021 | -16.29M |
| June 30, 2021 | -19.19M |
| March 31, 2021 | -18.32M |
| December 31, 2020 | -14.38M |
| September 30, 2020 | -11.87M |
| June 30, 2020 | -8.554M |
| Date | Value |
|---|---|
| March 31, 2020 | -5.740M |
| December 31, 2019 | |
| September 30, 2019 | -7.615M |
| June 30, 2019 | -6.717M |
| March 31, 2019 | -3.122M |
| December 31, 2018 | -1.976M |
| September 30, 2018 | -0.5384M |
| June 30, 2018 | -0.3337M |
| March 31, 2018 | -0.2804M |
| December 31, 2017 | -2.549M |
| September 30, 2017 | 19.12M |
| June 30, 2017 | -1.759M |
| March 31, 2017 | -2.236M |
| December 31, 2016 | -3.777M |
| September 30, 2016 | -3.355M |
| June 30, 2016 | -3.720M |
| March 31, 2016 | -3.707M |
| December 31, 2015 | -3.607M |
| September 30, 2015 | -1.873M |
| June 30, 2015 | -1.673M |
| March 31, 2015 | -3.128M |
| December 31, 2014 | |
| September 30, 2014 | |
| June 30, 2014 | -2.238M |
| March 31, 2014 | -2.212M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 100.78M |
| Incyte Corp. | 507.66M |
| AbbVie, Inc. | 3.436B |
| Rezolute, Inc. | -13.74M |
| Alnylam Pharmaceuticals, Inc. | 326.72M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -329.92M |
| Cash from Financing (Quarterly) | 410.21M |
| Free Cash Flow | -68.29M |
| Free Cash Flow Per Share (Quarterly) | -0.4584 |
| Free Cash Flow to Equity (Quarterly) | -19.90M |
| Free Cash Flow to Firm (Quarterly) | -19.99M |
| Free Cash Flow Yield | -14.49% |